Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

halt-RONIN Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies

Coordinator
Universidad Complutense De Madrid, Spain
Runs
1 December 2022 to 30 November 2026
Status
Running
EU funding
€6.7m
Total cost
€6.7m
Partners
26 organisations in 6 countries
Type
Research and Innovation Action
Grant agreement
101095679

What the project is doing

In the project's own words, from its summary on CORDIS.

Non-alcoholic fatty liver disease (NAFLD) is a multifactorial chronic inflammatory disease that is prevalent in 1 of 4 individuals with a significant personal, socioeconomic and healthcare burden, especially at the later, more severe inflammatory stage of disease - non-alcoholic steatohepatitis (NASH). Despite the severe negative impact of the disease on society, NAFLD remains difficult to diagnose and treat. Additionally, the molecular mechanisms underlying the transition from health to fatty liver to NASH remain poorly understood due to the lack of models that faithfully reflect the complexity of human disease.

Hence, Halt-RONIN aims to uncover the early triggers of disease initiation and complex mechanistic drivers of disease progression by implementing a systems biology approach with integrative disease modelling resulting in opportunities for the improvement of the existing detection methods, providing a blueprint to inform personalized intervention strategies and drug discovery for NAFLD. To achieve this goal, Halt-RONIN will combine experimental data from advanced in vitro and in vivo models with multimodal data from extensive human NAFLD cohorts and biobanks and use in silico machine learning approaches, to discover new biomarkers and molecular targets specific to each stage of the health-to-disease transition.

By validating preclinical experimental findings with real-world data, RONIN will allow for the discovery of novel biomarkers and molecular targets that are specific to the individual patient’s pathology. Consequently, healthcare professionals will gain the tools and knowledge required to diagnose and establish guidelines for the prevention and treatment of inflammation-driven health to disease. As such, in the long-term RONIN will decrease the number of NAFL patients who progress into NASH and provide disease-modifying strategies to improve patient outcomes.

Topics

Who is involved

OrganisationCityCountryRole
Universidad Complutense De MadridMadridSpainCoordinator
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
Anaxomics Biotech SLBarcelonaSpainParticipant
Asociacion Centro De Investigacion Cooperativa En Biociencias Cic BioguneDerio VizcayaSpainParticipant
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainParticipant
Fundacion Instituto De Investigacion Marques De ValdecillaSantanderSpainParticipant
Fundacion Para La Gestion De La Investigacion En Salud De SevillaSevillaSpainThird party
Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro-MajadahondaMajadahondaSpainThird party
Fundacion Para La Investigacion De Malaga En Biomedicina Y SaludMalagaSpainThird party
Hospital Clinic De BarcelonaBarcelonaSpainThird party
Servicio Andaluz De SaludSevillaSpainParticipant
Servicio Cantabro De SaludSantanderSpainThird party
Servicio Madrileno De SaludMadridSpainParticipant
Universidad De MalagaMalagaSpainParticipant
Biopredic International SARLSaint-GregoireFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
SciliciumRennesFranceParticipant
Universite De RennesRennesFranceThird party
Faculdade de Farmácia da Universidade de LisboaLisboaPortugalParticipant
Universidade Nova De LisboaLisboaPortugalParticipant
Bilkent Universitesi VakifBilkent AnkaraTürkiyeParticipant
Izmir Biyotip Ve Genom MerkeziİzmirTürkiyeParticipant
Edinburgh Napier UniversityEdinburghUnited KingdomAssociatedpartner
The University of EdinburghEdinburghUnited KingdomAssociatedpartner
University of GlasgowGlasgowUnited KingdomAssociatedpartner
Emulate IncBostonUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI